Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4746792 | 0.88 | GPR119 (0.43) | GAARAB9AALDH1A1MAPK1MEN1 | |
| SCHEMBL5507540 | 0.78 | GAA (0.46) | GAARAB9AALDH1A1MAPK1MEN1 | |
| SCHEMBL4982747 | 0.77 | HPGD (0.54) | GAARAB9AALDH1A1MAPK1MEN1 | |
| SCHEMBL3963250 | 0.75 | HPGD (0.56) | ALDH1A1MAPK1MEN1KMT2AMAPT | |
| SCHEMBL2844411 | 0.74 | REN (0.49) | — | |
| SCHEMBL4755321 | 0.74 | FFAR1 (0.38) | GAARAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL2847273 | 0.73 | POLB (0.47) | ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL4755206 | 0.72 | POLB (0.52) | GAARAB9AALDH1A1MAPK1MEN1 | |
| SCHEMBL4071817 | 0.71 | ALDH1A1 (0.59) | GAAALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL17913800 | 0.71 | MEN1 (0.68) | GAAALDH1A1MAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179109-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100130471-A1 | Renin Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179109-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | GAA 35/4885RAB9A 236/4885ALDH1A1 1625/4885 |
| US-20100130471-A1 | Renin Inhibitors | ACE, REN, DNPEP | GAA 35/4885RAB9A 463/4885ALDH1A1 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.